These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

59 related items for PubMed ID: 989173

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Triphasic dose-lethality relationships for amphetamine and certain ring-substituted amphetamines in isolated or aggregated mice.
    Davis WM, Waters IW, Hatoum HT, Buelke JL, Braude MC.
    Res Commun Chem Pathol Pharmacol; 1977 Aug; 17(4):575-82. PubMed ID: 578333
    [No Abstract] [Full Text] [Related]

  • 3. Interactions of catecholaminergic receptor blockers with lethal doses of amphetamine or substituted amphetamines in mice.
    Davis WM, Hatoum HT, Waters IW.
    Res Commun Chem Pathol Pharmacol; 1978 Jul; 21(1):27-36. PubMed ID: 687391
    [Abstract] [Full Text] [Related]

  • 4. Comparison of cardiovascular, hyperthermic, and toxic effects of para-methoxyamphetamine (PMA) and 3, 4-methylenedioxyamphetamine (MDA).
    Nichols DE, Ilhan M, Long JP.
    Arch Int Pharmacodyn Ther; 1975 Mar; 214(1):133-40. PubMed ID: 1174022
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Pharmacology and toxicity of 3,4-methylenedioxyamphetamine, para-methoxyamphetamine and related dimethoxyamphetamines.
    Paton DM, Bell JI, Yee R, Cook DA.
    Proc West Pharmacol Soc; 1975 Mar; 18():229-31. PubMed ID: 1178673
    [No Abstract] [Full Text] [Related]

  • 7. Increased fixed-ratio performance and differential d- and l-amphetamine action following norepinephrine depletion by intraventricular 6-hydroxydopamine.
    Peterson DW, Sparber SB.
    J Pharmacol Exp Ther; 1974 Dec; 191(3):349-57. PubMed ID: 4427285
    [No Abstract] [Full Text] [Related]

  • 8. Comparison of 2, 5-dimethoxy-4-methylamphetamine (DOM) and d-amphetamine for in vivo efflux of catecholamines from rat brain.
    Vrbanac JJ, Tilson HA, Moore KE, Rech RH.
    Pharmacol Biochem Behav; 1975 Dec; 3(1):57-64. PubMed ID: 1129355
    [Abstract] [Full Text] [Related]

  • 9. Behavioral changes induced by 2,5-dimethoxy 4-methyl-amphetamine (DOM, STP) in primate dyads.
    Tyler CB, Schlemmer RF, Narasimhachari N, Davis JM.
    Commun Psychopharmacol; 1978 Dec; 2(4):337-42. PubMed ID: 103677
    [No Abstract] [Full Text] [Related]

  • 10. Cardiovascular effects of 2, 5-dimethoxy-4-methylamphetamine (DOM, STP).
    Cheng HC, Long JP, Barfknecht CF, Nichols DE.
    J Pharmacol Exp Ther; 1973 Aug; 186(2):345-54. PubMed ID: 4719787
    [No Abstract] [Full Text] [Related]

  • 11. The effects of 2,5-dimethoxy-4-methylamphetamine (DOM) on operant behavior: interactions with other neuroactive agents.
    Commissaris RL, Semeyn DR, Moore KE, Rech RH.
    Commun Psychopharmacol; 1980 Aug; 4(5):393-404. PubMed ID: 6120791
    [No Abstract] [Full Text] [Related]

  • 12. Intensification of amphetamine-induced excitation by methysergide, a serotonergic receptor blocker.
    Blum K, Wallace JE, Meyer E, Schwertner HA.
    Experientia; 1977 Feb 15; 33(2):213-5. PubMed ID: 844561
    [Abstract] [Full Text] [Related]

  • 13. Effects of 3,4-methylenedioxymethamphetamine and related amphetamines on autonomic and behavioral thermoregulation.
    Jaehne EJ, Salem A, Irvine RJ.
    Pharmacol Biochem Behav; 2005 Jul 15; 81(3):485-96. PubMed ID: 15904952
    [Abstract] [Full Text] [Related]

  • 14. [Comparative study of the effects of amphetamine and dimethoxymethamphetamine on brain self-stimulation in rats after perinatal administration of 6-hydroxydopamine].
    Shabanov PD, Lebedev AA.
    Eksp Klin Farmakol; 2004 Jul 15; 67(6):12-5. PubMed ID: 15707006
    [Abstract] [Full Text] [Related]

  • 15. Gas chromatographic analysis of amphetamine derivatives and morpholine-related drugs.
    Canfield DV, Lorimer P, Epstein RL.
    J Forensic Sci; 1977 Apr 15; 22(2):429-33. PubMed ID: 582039
    [No Abstract] [Full Text] [Related]

  • 16. Behavioral effects of the beta3 adrenoceptor agonist SR58611A: is it the putative prototype of a new class of antidepressant/anxiolytic drugs?
    Consoli D, Leggio GM, Mazzola C, Micale V, Drago F.
    Eur J Pharmacol; 2007 Nov 14; 573(1-3):139-47. PubMed ID: 17669397
    [Abstract] [Full Text] [Related]

  • 17. The effect of dopamine uptake blocking agents on the amphetamine-induced circling behavior in mice with unilateral nigro-striatal lesions.
    Fung YK, Uretsky NJ.
    J Pharmacol Exp Ther; 1980 Sep 14; 214(3):651-6. PubMed ID: 6772760
    [Abstract] [Full Text] [Related]

  • 18. Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse.
    O'Callaghan JP, Miller DB.
    J Pharmacol Exp Ther; 1994 Aug 14; 270(2):741-51. PubMed ID: 8071867
    [Abstract] [Full Text] [Related]

  • 19. Differentiation of pressor and behavioral effects of d-amphetamine and 2,5-dimethoxy-4-methylamphetamine (STP) by cinanserin.
    Huang JT, Ho BT.
    Can J Physiol Pharmacol; 1973 Dec 14; 51(12):976-80. PubMed ID: 4777246
    [No Abstract] [Full Text] [Related]

  • 20. Influence of previous housing history on the toxicity of amphetamine in aggregate mice.
    Vargas-Rivera J, Ortega-Corona BG, García-Pineda J, Carranza J, Salazar LA, Villarreal J.
    Arch Invest Med (Mex); 1990 Dec 14; 21(1):65-9. PubMed ID: 2222118
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.